Rigel, MD Anderson partner to expand REZLIDHIA assessment in AML
AML is a fast-developing cancer originating in the blood and bone marrow, impacting myeloid cells that typically transform into different types of mature blood cells. REZLIDHIA is a
Merck, referred as MSD outside the US and Canada, has confirmed that Health Canada has approved a new indication for PREVYMIS (letermovir) to prevent cytomegalovirus (CMV) disease in high risk adult kidney transplant recipients.
The new, first-in-class inhibitor is being assessed to treat a range of immune-mediated disorders, including lupus nephritis (LN), the most common secondary immune-mediated glomerular disease. Following the acceptance,